Research synthesisModerate evidenceSmall effect7 studies · 4 beneficial · 3 neutral · 0 harmful
Across 7 studies, 4 reported beneficial small-sized effects of L-carnitine supplementation on reducing low-density lipoprotein (LDL) cholesterol, while 3 found no significant effect. The most commonly studied dose was 1 g/day, and effects were typically observed in clinical populations (type 2 diabetes, polycystic ovary syndrome, hemodialysis) over a median duration of 77 days (≈11 weeks). The overall evidence suggests a modest LDL-lowering benefit, but the effect is small and not consistently observed across all subgroups.
- Effective dose range: 1 g/day (1000 mg/day)
- Studied populations: people with type 2 diabetes, polycystic ovary syndrome, or undergoing hemodialysis
Caveats: The effect is modest and inconsistent across populations; three of seven studies (including two RCTs) showed no significant LDL reduction, particularly in hemodialysis patients. Most evidence comes from meta-analyses of clinical populations, so generalizability to healthy adults is unclear. No form data were reported, so potential differences between L-carnitine forms (e.g., L-carnitine tartrate vs. acetyl-L-carnitine) could not be assessed. The median study duration was ~11 weeks, leaving longer-term effects unknown.
Generated Jul 15, 2026